Trade CHRS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Coherus Oncology, Inc. (CHRS) is trading at US$1.35, up 9.76% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$219.39M. Over the past 52 weeks, CHRS has traded between US$1.09 and US$2.62. On Syfe you can trade CHRS with $0 commission and add it to your watchlist.
| Previous close | US$1.23 |
|---|---|
| Market cap | US$219.39M |
| 52-week range | US$1.09 – US$2.62 |
| Volume | 3.12M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Coherus Oncology, Inc.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Year: 2014
--Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30
Aug 17, 9:53 PM · MT Newswires
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics
Jun 23, 7:07 PM · MT Newswires
Coherus Oncology, Inc. (CHRS) stock is trading at US$1.35, +9.76% from the previous close of US$1.23.
The market cap for Coherus Oncology, Inc. (CHRS) stock is approximately US$219.39M.
The 52-week high for Coherus Oncology, Inc. (CHRS) stock is US$2.62.
The 52-week low for Coherus Oncology, Inc. (CHRS) stock is US$1.09.
Coherus Oncology, Inc. (CHRS) does not currently pay a dividend.
Stay on top of CHRS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
